The discovery and status of sibutramine as an anti-obesity drug

European Journal of Pharmacology

Volumn 440, Issue 2-3, 2002, Pages 119-128

  Luque, Carla A ^b   Rey, Jose A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Tel: +1 954 262 1362 ^*  (United States)

Author keywords

Obesity; Serotonin norepinephrine reuptake inhibitor; Sibutramine; Thermogenesis; Weight loss

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ANTIOBESITY AGENT; BETA 3 ADRENERGIC RECEPTOR; DESIPRAMINE; DEXFENFLURAMINE; DOPAMINE RECEPTOR; DRUG METABOLITE; FENFLURAMINE; FLUOXETINE; METERGOLINE; METOPROLOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN; PRAZOSIN; RITANSERIN; SEROTONIN; SEROTONIN ANTAGONIST; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; DIABETIC OBESITY; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENERGY EXPENDITURE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOPHAGIA; NONHUMAN; NORADRENALIN RELEASE; OBESITY; PRIORITY JOURNAL; SEROTONIN UPTAKE; THERMOGENESIS; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BODY WEIGHT; CLINICAL TRIALS; CYCLOBUTANES; HUMANS; OBESITY; WEIGHT LOSS;

EID: 0037066583     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01423-1     Document Type: Article

References (67)

1. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine
2. Absence of cardiac valve dysfunction in obese patients treated with sibutramine
3. Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat and hypothalamic extracellular fluid
4. Reciprocal relation of food intake and sympathetic activity: Experimental observations and clinical implications
5. BTS 54524, a monoamine uptake inhibitor exhibiting potent actions in models predictive of potential antidepressant activity
6. The putative antidepressant BTS 54524 rapidly and potently down-regulates cortical β-adrenoceptors in the rat
7. The pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant which induces rapid noradrenergic down-regulation
8. Valvular heart disease associated with dexfenfluramine (letter)
9. 3H]5-HT uptake: Effect of administration of various antidepressant treatments
10. 2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function
11. 3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments
12. Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine
13. Sibutramine: A new weight loss agent without evidence of the abuse potential associated with amphetamines
14. A study in rats of the effects of sibutramine on food intake and thermogenesis (abstract)
15. Role of β-adrenoceptors in mediating the thermogenic effects of sibutramine (abstract)
16. Thermogenic effects of sibutramine and its metabolites
17. Valvular heart disease associated with fenfluramine-phentermine
18. Six-month treatment of obesity with sibutramine 15 mg; A double-blind, placebo-controlled monocenter clinical trial in a Hispanic population
19. Sibutramine and thermogenesis in humans
20. Dexfenfluramine: An updated review of its therapeutic use in the management of obesity
21. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity
22. Effects of metabolites 1 and 2 of sibutramine on the short-term control of food intake in the rat (abstract)
23. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomized, double-blind, placebo-controlled study
24. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus
25. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor
26. Effects in the rat of sibutramine on food intake and the behavioral satiety sequence (abstract)
27. Thermogenic effects of sibutramine in humans
28. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
29. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients
30. 2-andrenoceptors in rat cortex
31. 2-adrenoceptor function in the brain: Rapid down-regulation by sibutramine hydrochloride
32. A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: Evidence that dopamine is not a pharmacologic target for sibutramine
33. 2-adrenoceptors exclusively by sibutramine hydrochloride
34. Sibutramine: A novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-amphetamine and D-fenfluramine
35. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents
36. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat
37. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat
38. Effect of sibutramine on weight maintenance after weight loss: A randomised trial
39. Long term weight loss with sibutramine: 5% responders (abstract)
40. Long-term weight loss with sibutramine (abstract)
41. Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry
42. Sibutramine weight loss in depressed patients
43. Phenylpropanolamine and the risk of hemorrhagic stroke
44. Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers
45. Effect of sibutramine on tissue glucose utilization in the rat (abstract)
46. Sibutramine: A serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity
47. The contribution of metabolites to the rapid and potent down-regulation of rat cortical β-adrenoceptors by the putative antidepressant sibutramine hydrochloride
48. Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl
49. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine
50. Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants
51. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of the evidence
52. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial
53. Dexfenfluramine: A review of its pharmacological properties and the therapeutic potential in obesity
54. Sibutramine reduces food intake in non-dieting women with obesity
55. Abuse liability assessment of sibutramine, a novel weight control agent
56. The effects of BTS 54 505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo
57. Effects of sibutramine on resting metabolic rate and weight loss in overweight women
58. Appetite suppressants: A review
59. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity
60. Influence of sibutramine on, energy expenditure in African-American women
61. Sibutramine: A review of the pharmacology of a novel anti obesity agent
62. Sibutramine effects on feeding behavior: A dose-dependence and microstructural analysis (abstract)
63. Effects of sibutramine on feeding behaviour in dietary-induced obesity: Role of dietary constituents
64. Effects of sibutramine on feeding behaviour in obese and lean Zucker rats (abstract)
65. Eating disorder and epilepsy in mice lacking 5-HT-2c serotonin receptors
66. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial
67. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females